<a href="https://www.fiercebiotech.com/biotech/gsk-walks-away-100m-bet-mersana-sting-adc-pauses-mrna-bird-flu-shot" hreflang="en">GSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot program</a>
GSK has terminated its $100 million partnership with Mersana Therapeutics regarding the STING-agonist antibody-drug conjugate XMT-2056, following safety concerns that arose during clinical trials. Additionally, GSK has paused its mRNA bird flu vaccine program to focus on its seasonal flu vaccine development.
The key insight for you is that GSK's decision to drop its $100M investment in Mersana's STING ADC, XMT-2056, highlights the high-risk nature of ADC development, especially given clinical trial challenges such as serious adverse events. This underscores the importance of rigorous early-phase clinical data evaluation before large-scale investment, which is crucial for stakeholders in healthtech and biotech sectors involved in drug discovery and development.